This report answers a single question: what is this 58-year-old's cholesterol-driven cardiovascular risk, and what should be done about it. The lipid panel shows a consolidating atherogenic pattern — a rising LDL, a low and falling HDL, and high triglycerides — layered on early insulin resistance, with two residual-risk markers (lipoprotein(a) and homocysteine) widening the picture beyond LDL alone. The sections that follow move from a snapshot of the current values, through their eighteen-month trajectory and the patterns that connect them, to an estimate of composite cardiovascular risk, concrete recommendations, and the data gaps that still limit the picture.
This snapshot reads as a single atherogenic lipid pattern rather than one isolated high number. LDL cholesterol is 165 mg/dL and climbing, HDL is low at 38 mg/dL, and triglycerides are 210 mg/dL — the dyslipidemia typical of insulin resistance. Two markers widen the picture beyond the standard panel: lipoprotein(a) at 78 nmol/L, a largely genetic, LDL-independent risk factor, and homocysteine at 14.2 µmol/L. Set against a rising HbA1c, a raised hs-CRP and a borderline blood pressure, the composite cardiovascular risk is higher than any single lipid value suggests.
| Marker | Result | Reference | Status | Trend |
|---|---|---|---|---|
| LDL Cholesterol | 165 mg/dL | <100 | high | |
| HDL Cholesterol | 38 mg/dL | >40 | low | |
| Triglycerides | 210 mg/dL | <150 | high | |
| Total Cholesterol | 245 mg/dL | <200 | high | — |
| Lipoprotein(a) | 78 nmol/L | <75 | high | — |
| HbA1c | 6.1 % | 4.0 - 5.6 | high | |
| hs-CRP | 3.4 mg/L | <1.0 | high | |
| Homocysteine | 14.2 µmol/L | <10 | high | — |
| Systolic Blood Pressure | 138 mmHg | <120 | high | — |
| Diastolic Blood Pressure | 88 mmHg | <80 | high | — |
- 2024-09-14
Baseline panel already shows an atherogenic lipid pattern.
LDL CholesterolBaseline high→ LipidsLDL opens at 142 mg/dL, already above the 100 mg/dL target.
HDL CholesterolBaseline low→ LipidsHDL is 43 mg/dL, sitting at the low end of the protective range.
TriglyceridesBaseline high→ LipidsTriglycerides 168 mg/dL, above the 150 mg/dL ceiling.
- 2025-06-11
Lipids drift further as insulin resistance advances.
LDL CholesterolRisingPrev: 142→ LipidsLDL climbs to 158 mg/dL.
HDL CholesterolFallingPrev: 43→ LipidsHDL slips to 40 mg/dL.
TriglyceridesRisingPrev: 168→ LipidsTriglycerides rise to 190 mg/dL.
hs-CRPRisingPrev: 1.8→ Inflammationhs-CRP rises to 2.6 mg/L, tracking the metabolic load behind the lipids.
- 2026-03-18
Latest panel confirms a consolidating atherogenic profile.
LDL CholesterolRisingPrev: 158→ LipidsLDL reaches 165 mg/dL.
HDL CholesterolFallingPrev: 40→ LipidsHDL falls to 38 mg/dL.
TriglyceridesRisingPrev: 190→ LipidsTriglycerides at 210 mg/dL.
Lipoprotein(a)Measured high→ Residual riskLipoprotein(a) measured at 78 nmol/L — a largely genetic, LDL-independent risk factor.
The lipid picture is best read as downstream of insulin resistance rather than a primary lipid disorder. Elevated fasting insulin and a HOMA-IR of 5.0 promote hepatic triglyceride output, which raises triglycerides, lowers HDL, and shifts LDL toward smaller, more atherogenic particles. Treating the insulin resistance is therefore likely to move LDL, HDL and triglycerides together.
A standard LDL of 165 mg/dL understates this patient's risk. Lipoprotein(a) at 78 nmol/L is a largely genetic, LDL-independent contributor a routine panel would miss, and homocysteine at 14.2 µmol/L adds an endothelial component. Combined with a borderline blood pressure, these stack to a higher composite risk than any single lipid value suggests.
The triglyceride-to-HDL ratio of roughly 5.5 (210 / 38) is a well-recognised marker of the small-dense-LDL, insulin-resistant phenotype and a practical surrogate when particle testing is unavailable. It reinforces that the risk here is qualitative, not just the LDL number.
Bringing the panel together into one estimate: with LDL 165 mg/dL, a low HDL, a raised lipoprotein(a) and a borderline blood pressure on a background of insulin resistance, this patient sits in an elevated ten-year cardiovascular-risk band. Standard calculators that lean on LDL alone understate the burden here because they omit the lipoprotein(a) and metabolic contributions — which is why the non-HDL and triglyceride/HDL surrogates are shown alongside.
Given an LDL of 165 mg/dL, a raised lipoprotein(a), a low HDL and a borderline blood pressure, a formal risk estimate and a statin discussion are warranted rather than lifestyle alone. A moderate-to-high-intensity statin would be the usual first step, with the intensity set by the ApoB and the calcium score below.
Because triglycerides are high and HDL low, the calculated LDL can under-read the true particle burden. An ApoB is the single highest-yield addition and would refine both the risk estimate and the treatment target.
A carbohydrate-aware diet with regular resistance and aerobic exercise and a 5–10% weight-loss target addresses the insulin resistance upstream of the lipids, so LDL, HDL, triglycerides and hs-CRP should improve together. A 3-month recheck confirms the direction.
A CAC score would reclassify this patient's risk and settle the treat / how-hard question, particularly given the raised lipoprotein(a). It is the most decisive single test to order alongside the ApoB.
The panel reports LDL cholesterol by calculation but not ApoB or particle number. With triglycerides high and HDL low, calculated LDL can under-represent the true atherogenic burden, so the LDL of 165 mg/dL may understate risk. An ApoB is the single highest-yield addition and would set the treatment intensity.
No imaging is available to stage subclinical atherosclerosis. Given the combined lipid, lipoprotein(a) and metabolic risk, a CAC score would reclassify this patient's 10-year risk and clarify whether — and how aggressively — to treat.
Lipoprotein(a) is largely genetic, yet only a single value is on file and no family history of premature cardiovascular disease is recorded. A confirmatory lipoprotein(a) and a family history would establish whether the raised 78 nmol/L carries inherited significance for relatives too.
A single office blood pressure of 138/88 cannot establish sustained hypertension, and weight, BMI and waist circumference are not recorded. Home or ambulatory monitoring plus basic anthropometrics are needed to interpret the cardiometabolic risk that compounds the lipid picture.
No current or prior statin, ezetimibe, or other lipid-lowering exposure is documented. Whether these values are on- or off-treatment changes their entire interpretation, so a reconciled medication history is a prerequisite before any therapeutic conclusion.
